Aug 26 (Reuters) - VBI Vaccines Inc said on
Wednesday it expected to begin human testing of two of its
experimental COVID-19 vaccine candidates at the end of the year.
The two candidates, VBI-2901 and VBI-2902, were selected
after three pre-clinical mouse studies induced neutralizing
antibodies after a single dose, the company said.
The activity was analyzed using a plaque reduction
neutralization test, considered the gold standard for measuring
antibodies that can neutralize a virus, the company said.
VBI said its manufacturing partner, Therapure
Biomanufacturing, will begin making bulk vaccines in September
for use through mid-stage trials.
VBI, which was this month awarded C$56 million ($42 million)
by the Canadian government to accelerate its COVID-19 vaccine
development program, is one of the many companies racing to
produce a safe and effective vaccine against the virus.
Many vaccine candidates are already in later stage of
Shares of the company rose 3.8% before the bell.
($1 = 1.32 Canadian dollars)
(Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj